4/17
08:19 am
ptct
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results [Yahoo! Finance]
Low
Report
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results [Yahoo! Finance]
4/17
08:00 am
ptct
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results
Low
Report
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results
3/31
04:17 pm
ptct
PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies [Yahoo! Finance]
Medium
Report
PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies [Yahoo! Finance]
3/31
10:45 am
ptct
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target lowered by analysts at JPMorgan Chase & Co. from $78.00 to $75.00. They now have an "overweight" rating on the stock.
Medium
Report
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target lowered by analysts at JPMorgan Chase & Co. from $78.00 to $75.00. They now have an "overweight" rating on the stock.
3/28
04:30 pm
ptct
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/28
09:00 am
ptct
PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe
Low
Report
PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe
3/24
10:58 am
ptct
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion [Yahoo! Finance]
Low
Report
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion [Yahoo! Finance]
3/20
08:00 am
ptct
PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies
Medium
Report
PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies
3/14
10:55 am
ptct
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at JPMorgan Chase & Co. from $72.00 to $78.00. They now have an "overweight" rating on the stock.
Low
Report
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at JPMorgan Chase & Co. from $72.00 to $78.00. They now have an "overweight" rating on the stock.
3/11
08:10 am
ptct
PTC Therapeutics, Inc. (NASDAQ: PTCT) was upgraded by analysts at Bank of America Co. from an "underperform" rating to a "neutral" rating. They now have a $55.00 price target on the stock, up previously from $41.00.
Low
Report
PTC Therapeutics, Inc. (NASDAQ: PTCT) was upgraded by analysts at Bank of America Co. from an "underperform" rating to a "neutral" rating. They now have a $55.00 price target on the stock, up previously from $41.00.
3/7
12:54 pm
ptct
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $70.00 price target on the stock, up previously from $67.00.
Low
Report
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $70.00 price target on the stock, up previously from $67.00.
3/7
08:40 am
ptct
PTC Therapeutics, Inc. (NASDAQ: PTCT) is now covered by analysts at Scotiabank. They set a "sector perform" rating and a $55.00 price target on the stock.
Low
Report
PTC Therapeutics, Inc. (NASDAQ: PTCT) is now covered by analysts at Scotiabank. They set a "sector perform" rating and a $55.00 price target on the stock.
3/3
09:53 am
ptct
$5.2 Bn Duchenne Muscular Dystrophy Market Opportunity Analysis and Forecasts, 2023-2024 & 2025-2033: Focus on US, France, Germany, Italy, Spain, UK, Japan [Yahoo! Finance]
Medium
Report
$5.2 Bn Duchenne Muscular Dystrophy Market Opportunity Analysis and Forecasts, 2023-2024 & 2025-2033: Focus on US, France, Germany, Italy, Spain, UK, Japan [Yahoo! Finance]
3/1
08:24 am
ptct
We Might See A Profit From PTC Therapeutics, Inc. (NASDAQ:PTCT) Soon [Yahoo! Finance]
Medium
Report
We Might See A Profit From PTC Therapeutics, Inc. (NASDAQ:PTCT) Soon [Yahoo! Finance]
2/28
12:06 pm
ptct
Q4 2024 PTC Therapeutics Inc Earnings Call [Yahoo! Finance]
Low
Report
Q4 2024 PTC Therapeutics Inc Earnings Call [Yahoo! Finance]
2/28
11:37 am
ptct
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target lowered by analysts at JPMorgan Chase & Co. from $74.00 to $72.00. They now have an "overweight" rating on the stock.
Low
Report
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target lowered by analysts at JPMorgan Chase & Co. from $74.00 to $72.00. They now have an "overweight" rating on the stock.
2/28
10:53 am
ptct
PTC Therapeutics Inc (PTCT) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ... [Yahoo! Finance]
Low
Report
PTC Therapeutics Inc (PTCT) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ... [Yahoo! Finance]
2/28
10:53 am
ptct
PTC Therapeutics (PTCT) Reports Q4 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
Low
Report
PTC Therapeutics (PTCT) Reports Q4 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
2/27
04:26 pm
ptct
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
High
Report
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
2/27
04:01 pm
ptct
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Medium
Report
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
2/20
08:32 am
ptct
PTC Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
PTC Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
2/20
08:00 am
ptct
PTC Therapeutics to Participate in Upcoming Investor Conferences
Medium
Report
PTC Therapeutics to Participate in Upcoming Investor Conferences
2/19
07:23 am
ptct
PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia [Yahoo! Finance]
Low
Report
PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia [Yahoo! Finance]
2/19
07:00 am
ptct
PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia
Low
Report
PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia
2/18
04:03 pm
ptct
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Royal Bank of Canada from $60.00 to $63.00. They now have an "outperform" rating on the stock.
Low
Report
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Royal Bank of Canada from $60.00 to $63.00. They now have an "outperform" rating on the stock.